Savant Capital LLC Sells 2,686 Shares of Natera, Inc. $NTRA

Savant Capital LLC cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 7.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,228 shares of the medical research company’s stock after selling 2,686 shares during the quarter. Savant Capital LLC’s holdings in Natera were worth $5,276,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of NTRA. Resona Asset Management Co. Ltd. increased its position in Natera by 9.6% during the second quarter. Resona Asset Management Co. Ltd. now owns 40,848 shares of the medical research company’s stock worth $6,895,000 after acquiring an additional 3,588 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Natera by 283.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 18,571 shares of the medical research company’s stock worth $3,142,000 after purchasing an additional 13,734 shares during the last quarter. Machina Capital S.A.S. bought a new position in shares of Natera during the 2nd quarter worth about $362,000. Mission Wealth Management LP acquired a new position in shares of Natera during the second quarter valued at about $228,000. Finally, Zweig DiMenna Associates LLC lifted its stake in shares of Natera by 3.0% in the second quarter. Zweig DiMenna Associates LLC now owns 124,100 shares of the medical research company’s stock valued at $20,965,000 after buying an additional 3,610 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $199.57 on Friday. The business’s fifty day moving average price is $177.75 and its two-hundred day moving average price is $163.81. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $203.23. The stock has a market capitalization of $27.39 billion, a price-to-earnings ratio of -87.15 and a beta of 1.75.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, November 6th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.20%. The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) EPS. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. BNP Paribas raised Natera to a “hold” rating and set a $172.00 price objective on the stock in a report on Monday, October 27th. Canaccord Genuity Group upped their target price on Natera from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Natera from $210.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday. Seventeen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $206.74.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 160,703 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the transaction, the chief executive officer directly owned 144,816 shares of the company’s stock, valued at $28,957,407.36. The trade was a 52.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 2,491 shares of the stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $162.05, for a total value of $403,666.55. Following the sale, the chief financial officer owned 69,189 shares in the company, valued at approximately $11,212,077.45. This trade represents a 3.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 224,889 shares of company stock valued at $43,232,062 in the last ninety days. 5.63% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.